Prostate Cancer Specialist in Guatemala
Prostate cancer has multiple stages. Each one with a different treatment.
Hormone-sensitive, castration-resistant, high-risk localized — these aren't the same disease. The right treatment depends on the stage, the PSA, the tumor's biology, and prior treatments.
When should you consult Dr. Reynoso?
You were diagnosed with prostate cancer and need a medical oncology evaluation
Your PSA is rising despite hormone therapy
You were told the cancer is castration-resistant and don't know what comes next
You have bone metastases and are looking for systemic treatment options
You want a second opinion before starting or changing treatment
Your urologist recommended adding chemotherapy or next-generation hormone therapy
⚡ Consultations Monday, Tuesday, and Thursday | By appointment only
95%+
5-year survival rate for localized prostate cancer with appropriate treatment
3+
lines of treatment available for castration-resistant prostate cancer
8+
years managing prostate cancer at every stage in Guatemala
Q600
initial consultation with complete case review and treatment plan
It's not one disease. It's several stages.
Prostate cancer evolves through stages with distinct biology and treatments. High-risk localized disease requires a decision between surgery, radiotherapy, and adjuvant hormone therapy. Hormone-sensitive metastatic disease responds to androgen deprivation therapy plus next-generation agents. Castration-resistant disease requires a completely different strategy.
The medical oncologist becomes involved in prostate cancer management when local treatment isn't enough or when the disease has spread. He defines the systemic component — hormone therapy, chemotherapy, PARP inhibitors — in coordination with urology and radiotherapy.
“Castration-resistant prostate cancer isn't the end. There's enzalutamide, abiraterone, docetaxel, cabazitaxel, PARP inhibitors for BRCA-mutated cases — the right choice depends on prior treatments and the tumor's profile.”—Dr. Giovanni Reynoso
Symptoms and findings that require an oncologic evaluation.
Prostate cancer is often detected through elevated PSA before producing symptoms. When symptoms do appear, they generally indicate more advanced disease.
Elevated or rising PSA
Elevated prostate-specific antigen on routine testing, or a progressive rise across serial measurements. It's the most important signal for early oncology referral.
Obstructive urinary symptoms
Difficulty starting urination, weak stream, urinary urgency, or frequent urination. Common in locally advanced prostate cancer — though also symptoms of benign hyperplasia.
Bone pain
Persistent pain in the spine, pelvis, hips, or ribs. Prostate cancer frequently metastasizes to bone — bone pain in a patient with a prior diagnosis is a warning sign.
Rising PSA on hormone therapy
PSA elevation despite testosterone levels in the castration range. Defines castration resistance — and requires a change in therapeutic strategy.
Finding on prostate biopsy
Adenocarcinoma on ultrasound- or MRI-guided biopsy — with a Gleason score and number of positive cores that determine risk and treatment.
Pathological fracture
A fracture from minimal trauma in a patient with known prostate cancer. Indicates bone metastasis at that location and requires urgent evaluation.
Do you identify with any of these?
A first one-hour consultation is enough to begin your workup and, if applicable, reach a clear diagnosis
PSA rising despite treatment. It doesn't mean the options have run out.
Castration resistance is one of the most distressing moments in prostate cancer. PSA rises, the hormone therapy that used to work no longer works, and the question is what comes next. The answer depends on the tumor's profile and prior treatments — and there are more options than many patients know about.
Castration resistance without a change in strategy
Many patients with castration-resistant prostate cancer stay on the same hormone therapy that stopped working. Enzalutamide, abiraterone, and darolutamide are next-generation agents specifically indicated at this point — and they make a significant difference.
Metastatic disease without BRCA testing
In metastatic castration-resistant prostate cancer, the presence of BRCA1, BRCA2, or other DNA repair gene mutations opens access to PARP inhibitors — olaparib, rucaparib — with significant responses. Without testing, that option doesn't exist for the patient.
Progression after enzalutamide or abiraterone
Progression on next-generation agents doesn't close off the options. Docetaxel, cabazitaxel, and, in selected cases, radium-223 for predominantly bone metastases are available treatment lines with demonstrated benefit.
“Castration-resistant doesn't mean no options. It means we change strategy — and there are several available. The key is knowing which one fits that patient at that moment.”—Dr. Giovanni Reynoso
How prostate cancer is evaluated in an oncology consultation
The medical oncology consultation for prostate cancer complements urological management. Dr. Reynoso defines the systemic component of treatment — when to add hormone therapy, which agent, and when to switch lines.
Complete case review
Detailed medical history, PSA trend, biopsy result with Gleason score, imaging studies, and prior treatments — surgical, radiotherapy, and hormonal.
Risk classification and staging
Classification by risk group (low, intermediate, high, very high) in localized disease. In metastatic disease, determination of disease volume — high or low volume — and hormonal status — hormone-sensitive or castration-resistant.
Biomarker evaluation when applicable
Mutations in BRCA1, BRCA2, and other homologous recombination DNA repair genes in metastatic castration-resistant prostate cancer — determine access to PARP inhibitors (olaparib, rucaparib).
Defining the systemic component
The medical oncologist defines when and with which agent to start or escalate systemic treatment — androgen deprivation therapy, next-generation agents, chemotherapy, or PARP inhibitors.
Coordination with urology and radiotherapy
In high-risk localized disease, the multidisciplinary plan integrates surgery, radiotherapy, and hormone therapy. Dr. Reynoso defines the systemic component within that context.
Follow-up and management of progression
Monitoring PSA, imaging, and treatment response. Determining when to switch lines and which agent to use in the next strategy.
Why consult Dr. Reynoso for prostate cancer?
Management of every stage of the disease
From high-risk localized cancer to castration-resistant disease — Dr. Reynoso manages every stage of prostate cancer with the most up-to-date ASCO and ESMO protocols.
Access to next-generation therapies
Enzalutamide, abiraterone, darolutamide, apalutamide, olaparib, rucaparib — Dr. Reynoso knows the indications, treatment sequences, and criteria for switching lines for each of these agents.
BRCA evaluation and PARP inhibitors
In metastatic castration-resistant prostate cancer, the presence of BRCA mutations or other DNA repair gene mutations opens access to PARP inhibitors — a powerful option that requires molecular testing to identify it.
Real coordination with urology and radiotherapy
Prostate cancer is a multidisciplinary disease. Dr. Reynoso defines the systemic component in coordination with the urology and radiotherapy team — not in isolation.
Management of every stage of the disease
From high-risk localized cancer to castration-resistant disease — Dr. Reynoso manages every stage of prostate cancer with the most up-to-date ASCO and ESMO protocols.
Access to next-generation therapies
Enzalutamide, abiraterone, darolutamide, apalutamide, olaparib, rucaparib — Dr. Reynoso knows the indications, treatment sequences, and criteria for switching lines for each of these agents.
BRCA evaluation and PARP inhibitors
In metastatic castration-resistant prostate cancer, the presence of BRCA mutations or other DNA repair gene mutations opens access to PARP inhibitors — a powerful option that requires molecular testing to identify it.
Real coordination with urology and radiotherapy
Prostate cancer is a multidisciplinary disease. Dr. Reynoso defines the systemic component in coordination with the urology and radiotherapy team — not in isolation.
Received a cancer diagnosis? The next step is a consultation.
First visit, second opinion, or oncologic follow-up — you deserve an oncologist who explains everything.
Medical Oncology in Guatemala City
Dr. Giovanni Reynoso - Oncólogo
Edificio Spazio, 15 avenida y 5 calle 5-50, Vista Hermosa III, Zona 15. Nivel 10, Oficina 10-01Bonanova Health, private hospital specializing in cancer in Zona 15
Office Hours
Monday to Tuesday from 4:00 PM to 6:00 PM Thursday from 3:00 PM to 5:00 PM
Emergency Care
Dr. Reynoso does not handle emergencies. For oncologic emergencies, go to the nearest hospital.
Coverage Areas
Guatemala City
- • Zona 15, Vista Hermosa I, II, and III
- • Zona 10, 14, 16
- • Zona 9, 13
- • Carretera a El Salvador
Metropolitan Area
- • Mixco
- • Villa Nueva
- • Santa Catarina Pinula
- • San Cristóbal
Departmental Coverage
- • All departments of Guatemala
- • Patients traveling from other parts of the country
- • Zacapa, Chiquimula, Izabal, San Marcos, Petén
International Coverage
- • El Salvador
- • Belize
- • Honduras
- • Costa Rica
Common questions, clear answers
Still have questions? Let’s talk directly on WhatsApp for personalized answers.